128 related articles for article (PubMed ID: 11372681)
1. Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1.
Bijnens AP; Ngo TH; Gils A; Dewaele J; Knockaert I; Stassen JM; Declerck PJ
Thromb Haemost; 2001 May; 85(5):866-74. PubMed ID: 11372681
[TBL] [Abstract][Full Text] [Related]
2. Importance of N-terminal residues in plasminogen activator inhibitor 1 on its antibody induced latency transition.
Ngo TH; Zhou Y; Stassen JM; Declerck PJ
Thromb Haemost; 2002 Aug; 88(2):288-93. PubMed ID: 12195702
[TBL] [Abstract][Full Text] [Related]
3. High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I).
Stoop AA; Jespers L; Lasters I; Eldering E; Pannekoek H
J Mol Biol; 2000 Sep; 301(5):1135-47. PubMed ID: 10966811
[TBL] [Abstract][Full Text] [Related]
4. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
[TBL] [Abstract][Full Text] [Related]
5. Function-stabilizing mechanism of plasminogen activator inhibitor type 1 induced upon binding to alpha1-acid glycoprotein.
Smolarczyk K; Gils A; Boncela J; Declerck PJ; Cierniewski CS
Biochemistry; 2005 Sep; 44(37):12384-90. PubMed ID: 16156651
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
[TBL] [Abstract][Full Text] [Related]
7. Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop.
Debrock S; Declerck PJ
Thromb Haemost; 1998 Mar; 79(3):597-601. PubMed ID: 9531048
[TBL] [Abstract][Full Text] [Related]
8. Vitronectin and substitution of a beta-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against alpha-helix F.
Schousboe SL; Egelund R; Kirkegaard T; Preissner KT; Rodenburg KW; Andreasen PA
Thromb Haemost; 2000 May; 83(5):742-51. PubMed ID: 10823273
[TBL] [Abstract][Full Text] [Related]
9. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
[TBL] [Abstract][Full Text] [Related]
10. The distal hinge of the reactive site loop and its proximity: a target to modulate plasminogen activator inhibitor-1 activity.
Bijnens AP; Gils A; Stassen JM; Komissarov AA; Knockaert I; Brouwers E; Shore JD; Declerck PJ
J Biol Chem; 2001 Nov; 276(48):44912-8. PubMed ID: 11559698
[TBL] [Abstract][Full Text] [Related]
11. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1.
Bijnens AP; Knockaert I; Cousin E; Kruithof EK; Declerck PJ
Thromb Haemost; 1997 Feb; 77(2):350-6. PubMed ID: 9157595
[TBL] [Abstract][Full Text] [Related]
12. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding.
Wind T; Jensen MA; Andreasen PA
Eur J Biochem; 2001 Feb; 268(4):1095-106. PubMed ID: 11179976
[TBL] [Abstract][Full Text] [Related]
13. A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.
Mathiasen L; Dupont DM; Christensen A; Blouse GE; Jensen JK; Gils A; Declerck PJ; Wind T; Andreasen PA
Mol Pharmacol; 2008 Sep; 74(3):641-53. PubMed ID: 18559377
[TBL] [Abstract][Full Text] [Related]
14. A method for defining binding sites involved in protein-protein interactions: analysis of the binding of plasminogen activator inhibitor 1 to the somatomedin domain of vitronectin.
Royle G; Deng G; Seiffert D; Loskutoff DJ
Anal Biochem; 2001 Sep; 296(2):245-53. PubMed ID: 11554720
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.
De Taeye B; Gils A; Vleugels N; Rabijns A; Declerck PJ
Biochem Biophys Res Commun; 2004 Aug; 321(3):746-51. PubMed ID: 15358169
[TBL] [Abstract][Full Text] [Related]
16. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
[TBL] [Abstract][Full Text] [Related]
17. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
18. Elucidation of the paratope of scFv-8H9D4, a PAI-1 neutralizing antibody derivative.
Verbeke K; Gils A; Stassen JM; Declerck PJ
Thromb Haemost; 2003 Jan; 89(1):74-82. PubMed ID: 12540956
[TBL] [Abstract][Full Text] [Related]
19. Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies.
Bijnens AP; Gils A; Knockaert I; Stassen JM; Declerck PJ
J Biol Chem; 2000 Mar; 275(9):6375-80. PubMed ID: 10692438
[TBL] [Abstract][Full Text] [Related]
20. Characterization of recombinant rat plasminogen activator inhibitor-1 and development of immunological tools for its quantitation.
Ngo TH; Verheyen S; Knockaert I; Declerck PJ
J Pharm Belg; 1997; 52(4):165-6. PubMed ID: 9316343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
